Cellmid (ASX:CDY) Chief Executive and Managing Director Maria Halasz sat down with Christine Corrado from Proactive Investors New York to discuss their biotech company that now has products available in the United States.
Halasz telling Proactive they are about to spin out into 2 companies and she sees the company becoming profitable in 2020.
Price: 0.095 AUD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE
Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...
Prev article
